P. Janský
Economics and Econometrics · 2011–2019
A researcher in the Science corpus: 7 papers; trusts 16 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Economics and Econometrics — 23 citations into it; #15,594 of 23,481 by trust here, #22,774 by citations
- Accounting — 19 citations into it; #5,919 of 8,970 by trust here, #8,779 by citations
Whom P. Janský trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- G. Zucman
- Jane G. Gravelle
- Niels Johannesen
- Kimberly A. Clausing
- Ernesto Crivelli
- Gene M. Grossman
- Daniel Haberly
- S. Ali Abbas
Who trusts P. Janský overall
Papers from P. Janský's perspective
Ordered by how strongly the researchers P. Janský trusts endorse each paper. Same corpus, a different order for every researcher.
- Base Erosion, Profit Shifting and Developing Countries (Social Science Research Network)
- The End of Bank Secrecy? An Evaluation of the G20 Tax Haven Crackdown †
- Tax Havens: International Tax Avoidance and Evasion (National tax journal)
- Taxing across Borders: Tracking Personal Wealth and Corporate Profits
- Money Laundering and its Regulation
- The political economy of international tax governance
- Tax Havens and the Commercialization of State Sovereignty (International Organization)
- Trading Tasks: A Simple Theory of Offshoring
- Tax Havens and the Production of Offshore FDI: An Empirical Analysis
- Hard and Soft Law in International Governance (International Organization)
Their papers
- Global distribution of revenue loss from corporate tax avoidance: re‐estimation and country results (2018) — 252 citations
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. (2019) — 2,307 citations
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. (2016) — 744 citations
- The Financial Secrecy Index: Shedding New Light on the Geography of Secrecy (2015) — 139 citations
- Apixaban in patients with atrial fibrillation. (2011) — 2,210 citations
- Apixaban versus warfarin in patients with atrial fibrillation. (2011) — 4,096 citations
- Apixaban with antiplatelet therapy after acute coronary syndrome. (2011) — 910 citations